A Study Comparing Two Formulations of Insulin Glargine in Healthy Participants

Summary

The study will aim to evaluate the following: * Whether there are any differences in the way the body handles LY2963016 U-200 and LY2963016 U-100. * How well-tolerated LY2963016 U-200 is compared with LY2963016 U-100. * How LY2963016 U-200 affects the level of blood sugar in the body compared with LY2963016 U-100. The study will last up to 17 weeks for each participant, including initial screening and follow up.

Timeline

Start

2016-11-14

Primary completion

2017-01-04

Completion

2017-01-04

Drugs

Indications

No indication recorded.